Skip to main content

Advertisement

SpringerLink
Log in

Recent advances in the pathogenesis and diagnosis of liver fibrosis

  • Review
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828–1835.

    Article  PubMed  CAS  Google Scholar 

  2. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247–2250.

    Article  PubMed  CAS  Google Scholar 

  3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–218.

    PubMed  CAS  Google Scholar 

  4. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125–172.

    Article  PubMed  CAS  Google Scholar 

  5. Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003;28:105–112.

    Article  PubMed  CAS  Google Scholar 

  6. Yokoi Y, Namihisa T, Kuroda H, Komatsu I, Miyazaki A, Watanabe S, et al. Immunocytochemical detection of desmin in fat-storing cells (Ito cells). Hepatology 1984;4:709–714.

    Article  PubMed  CAS  Google Scholar 

  7. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001;21:311–335.

    Article  PubMed  CAS  Google Scholar 

  8. Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001;21:417–426.

    Article  PubMed  CAS  Google Scholar 

  9. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807–1816.

    Article  PubMed  CAS  Google Scholar 

  10. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007;22Suppl 1:S73–S78.

    Article  PubMed  CAS  Google Scholar 

  11. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis 1990;10:56–65.

    PubMed  CAS  Google Scholar 

  12. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–438.

    PubMed  CAS  Google Scholar 

  13. Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007;46:590–597.

    Article  PubMed  CAS  Google Scholar 

  14. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130:435–452.

    Article  PubMed  CAS  Google Scholar 

  15. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56–65.

    PubMed  CAS  Google Scholar 

  16. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004;127:870–882.

    Article  PubMed  CAS  Google Scholar 

  17. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005;115:3072–3082.

    Article  PubMed  CAS  Google Scholar 

  18. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007;26:117–129.

    Article  PubMed  CAS  Google Scholar 

  19. Unanue ER. Ito cells, stellate cells, and myofibroblasts: new actors in antigen presentation. Immunity 2007;26:9–10.

    Article  PubMed  CAS  Google Scholar 

  20. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043–1055.

    Article  PubMed  CAS  Google Scholar 

  21. Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G571–G578.

    Article  PubMed  CAS  Google Scholar 

  22. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.

    Article  PubMed  CAS  Google Scholar 

  23. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324–1332.

    Article  PubMed  CAS  Google Scholar 

  24. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007;46:1509–1518.

    Article  PubMed  CAS  Google Scholar 

  25. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ, et al. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 1999;30:761–769.

    Article  PubMed  CAS  Google Scholar 

  26. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005;128:108–120.

    Article  PubMed  CAS  Google Scholar 

  27. Oakley F, Mann J, Ruddell RG, Pickford J, Weinmaster G, Mann DA. Basal expression of IkappaBalpha is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notch1. J Biol Chem 2003;278:24359–24370.

    Article  PubMed  CAS  Google Scholar 

  28. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685–698.

    Article  PubMed  CAS  Google Scholar 

  29. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007;293:G631–G639.

    Article  PubMed  CAS  Google Scholar 

  30. De Minicis S, Brenner DA. NOX in liver fibrosis. Arch Biochem Biophys 2007;462:266–272.

    Article  PubMed  CAS  Google Scholar 

  31. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003;112:1383–1394.

    PubMed  CAS  Google Scholar 

  32. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006;43:435–443.

    Article  PubMed  CAS  Google Scholar 

  33. Adachi T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K, et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 2005;41:1272–1281.

    Article  PubMed  CAS  Google Scholar 

  34. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 2003;28:502–508.

    Article  PubMed  CAS  Google Scholar 

  35. Jiang J, Baghy K, Torok NJ. NOX2 and Rac1 play an important role liver fibrogenesis by facilitating phagocytosis of apoptotic bodies and production of ROS by stellate cells. Hepatology; 2007. p. 869A.

  36. Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151–1159.

    Article  PubMed  CAS  Google Scholar 

  37. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153–159.

    Article  PubMed  Google Scholar 

  38. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955–963.

    Article  PubMed  Google Scholar 

  39. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006;130:1807–1821.

    Article  PubMed  Google Scholar 

  40. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429–438.

    Article  PubMed  CAS  Google Scholar 

  41. Higashiyama R, Inagaki Y, Hong YY, Kushida M, Nakao S, Niioka M, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007;45:213–222.

    Article  PubMed  CAS  Google Scholar 

  42. Ishikawa T, Terai S, Urata Y, Marumoto Y, Aoyama K, Murata T, et al. Administration of fibroblast growth factor 2 in combination with bone marrow transplantation synergistically improves carbon-tetrachloride-induced liver fibrosis in mice. Cell Tissue Res 2007;327:463–470.

    Article  PubMed  CAS  Google Scholar 

  43. Nakamura T, Torimura T, Sakamoto M, Hashimoto O, Taniguchi E, Inoue K, et al. Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology 2007;133:91–107 e101.

    Article  PubMed  CAS  Google Scholar 

  44. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210.

    Article  PubMed  CAS  Google Scholar 

  45. Robertson H, Kirby JA, Yip WW, Jones DE, Burt AD. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007;45:977–981.

    Article  PubMed  CAS  Google Scholar 

  46. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007;282:22089–22101.

    Article  PubMed  CAS  Google Scholar 

  47. Ikegami T, Zhang Y, Matsuzaki Y. Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 2007;185:213–221.

    Article  PubMed  Google Scholar 

  48. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337–23347.

    Article  PubMed  CAS  Google Scholar 

  49. Kojima T, Takano KI, Yamamoto T, Murata M, Son S, Imamura M, et al. Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes. Liver Int 2008;28:534–545.

    PubMed  CAS  Google Scholar 

  50. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122:1525–1528.

    Article  PubMed  Google Scholar 

  51. Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004;279:4820–4828.

    Article  PubMed  CAS  Google Scholar 

  52. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001;21:427–436.

    Article  PubMed  CAS  Google Scholar 

  53. Goto T, Mikami KI, Miura K, Ohshima S, Yoneyama K, Nakane K, et al. Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells. Pathophysiology 2004;11:153–158.

    Article  PubMed  CAS  Google Scholar 

  54. Murphy FR, Isaa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069–11076.

    Article  PubMed  CAS  Google Scholar 

  55. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000;32:1248–1254.

    Article  PubMed  CAS  Google Scholar 

  56. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grotzinger J, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006;20:444–454.

    Article  PubMed  CAS  Google Scholar 

  57. Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependent MAPK pathways. J Biol Chem 2004;279:4292–4304.

    Article  PubMed  CAS  Google Scholar 

  58. Lin S, Saxena NK, Ding X, Stein LL, Anania FA. Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol 2006;20:3376–3388.

    Article  PubMed  CAS  Google Scholar 

  59. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007;22Suppl 1:S93–S95.

    Article  PubMed  CAS  Google Scholar 

  60. Serriere-Lanneau V, Teixeira-Clerc F, Li L, Schippers M, de Wries W, Julien B, et al. The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J 2007;21:2005–2013.

    Article  PubMed  CAS  Google Scholar 

  61. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558–563.

    PubMed  CAS  Google Scholar 

  62. Plebani M, Basso D. Non-invasive assessment of chronic liver and gastric diseases. Clin Chim Acta 2007;381:39–49.

    Article  PubMed  CAS  Google Scholar 

  63. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–798.

    Article  PubMed  CAS  Google Scholar 

  64. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373–1381.

    Article  PubMed  Google Scholar 

  65. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867–1873.

    Article  PubMed  CAS  Google Scholar 

  66. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078–1087.

    Article  PubMed  CAS  Google Scholar 

  67. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27–33.

    Article  PubMed  CAS  Google Scholar 

  68. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007;46:582–589.

    Article  PubMed  CAS  Google Scholar 

  69. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–526.

    Article  PubMed  Google Scholar 

  70. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–1075.

    Article  PubMed  CAS  Google Scholar 

  71. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986–992.

    PubMed  Google Scholar 

  72. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686–693.

    Article  PubMed  CAS  Google Scholar 

  73. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376–1382.

    Article  PubMed  Google Scholar 

  74. Pinzani M. Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched. Gut 2006;55:310–312.

    Article  PubMed  CAS  Google Scholar 

  75. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005;39:S158–S161.

    Article  PubMed  CAS  Google Scholar 

  76. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–350.

    Article  PubMed  Google Scholar 

  77. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48–54.

    Article  PubMed  Google Scholar 

  78. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403–408.

    Article  PubMed  CAS  Google Scholar 

  79. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43:1118–1124.

    Article  PubMed  Google Scholar 

  80. Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007;56:1330–1331.

    Article  PubMed  Google Scholar 

  81. Harada N, Soejima Y, Taketomi A, Yoshizumi T, Ikegami T, Yamashita Y, et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 2008;85:69–74.

    Article  PubMed  Google Scholar 

  82. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47:592–595.

    Article  PubMed  CAS  Google Scholar 

  83. Solga SF, Horska A, Clark JM, Diehl AM. Hepatic 31P magnetic resonance spectroscopy: a hepatologist’s user guide. Liver Int 2005;25:490–500.

    Article  PubMed  Google Scholar 

  84. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5:1207–1213 e1202.

    Article  PubMed  Google Scholar 

  85. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008;47:332–342.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, 4150, V Street Sacramento, CA, 95817, California, USA

    Natalie J. Török

Authors
  1. Natalie J. Török
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Török, N.J. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 43, 315–321 (2008). https://doi.org/10.1007/s00535-008-2181-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-008-2181-x

Key words

Search

Navigation